Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pfeffer

Showing results (701-710 of 754) with videos related to

Pageof 76
Sort By:
Clinical Trials (London, England)|April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challengesThomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research PracticesMatthew A Sparks, Andrew M South, Andrew D Badley, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of the American Heart Association|November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HFLeanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 25, 2018
Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT TrialDaniel E Weiner, Meyeon Park, Hocine Tighiouart, et al.
Circulation. Heart Failure|December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection FractionPooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Pageof 76

Showing results (701-710 of 754) with videos related to

Sort By:
Pageof 76
Clinical Trials (London, England)|April 1, 2017
Data monitoring committees: Promoting best practices to address emerging challengesThomas R Fleming, David L DeMets, Matthew T Roe, et al.
American Heart Journal|May 3, 2005
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney diseaseT-Christian H Mix, Robert M Brenner, Mark E Cooper, et al.
Hypertension (Dallas, Tex. : 1979)|September 28, 2020
Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: Pressing Needs and Best Research PracticesMatthew A Sparks, Andrew M South, Andrew D Badley, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
Journal of the American Heart Association|November 19, 2021
Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HFLeanne Mooney, Nathaniel M Hawkins, Pardeep S Jhund, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|July 25, 2018
Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT TrialDaniel E Weiner, Meyeon Park, Hocine Tighiouart, et al.
Circulation. Heart Failure|December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection FractionPooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Circulation|January 30, 2020
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future DirectionsAbhinav Sharma, Neha J Pagidipati, Robert M Califf, et al.
Circulation|November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trialMarc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Journal of Heart Failure|February 20, 2021
Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trialJoão Pedro Ferreira, Brian L Claggett, Jiankang Liu, et al.
Pageof 76